Insider Buying: Abrdn Life Sciences Investors (NYSE:HQL) Major Shareholder Acquires 10,986 Shares of Stock

Abrdn Life Sciences Investors (NYSE:HQL - Get Free Report) major shareholder Saba Capital Management, L.P. purchased 10,986 shares of the business's stock in a transaction on Wednesday, May 8th. The shares were acquired at an average price of $13.70 per share, with a total value of $150,508.20. Following the completion of the transaction, the insider now owns 3,140,590 shares of the company's stock, valued at $43,026,083. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their transactions with the SEC.

Saba Capital Management, L.P. also recently made the following trade(s):

• On Monday, May 6th, Saba Capital Management, L.P. bought 10,713 shares of Abrdn Life Sciences Investors stock. The shares were purchased at an average price of $13.62 per share, with a total value of $145,911.06.
• On Thursday, May 2nd, Saba Capital Management, L.P. bought 26,274 shares of Abrdn Life Sciences Investors stock. The shares were purchased at an average price of $13.46 per share, with a total value of $353,648.04.
• On Tuesday, April 30th, Saba Capital Management, L.P. bought 16,573 shares of Abrdn Life Sciences Investors stock. The shares were purchased at an average price of $13.13 per share, with a total value of $217,603.49.
• On Friday, April 26th, Saba Capital Management, L.P. bought 120,304 shares of Abrdn Life Sciences Investors stock. The shares were purchased at an average price of $13.00 per share, with a total value of $1,563,952.00.
• On Wednesday, April 24th, Saba Capital Management, L.P. bought 20,529 shares of Abrdn Life Sciences Investors stock. The shares were purchased at an average price of $13.12 per share, with a total value of $269,340.48.
• On Monday, April 22nd, Saba Capital Management, L.P. acquired 2,022 shares of Abrdn Life Sciences Investors stock. The stock was bought at an average price of $12.88 per share, with a total value of $26,043.36.
• On Thursday, April 18th, Saba Capital Management, L.P. acquired 81,738 shares of Abrdn Life Sciences Investors stock. The stock was bought at an average price of $12.80 per share, with a total value of $1,046,246.40.

Abrdn Life Sciences Investors Price Performance

Shares of NYSE HQL traded up $0.03 on Friday, reaching $13.85. 150,021 shares of the company's stock traded hands, compared to its average volume of 86,954. Abrdn Life Sciences Investors has a 12 month low of $11.34 and a 12 month high of $14.37. The business's 50 day simple moving average is $13.40 and its two-hundred day simple moving average is $13.20.

Hedge Funds Weigh In On Abrdn Life Sciences Investors

A number of institutional investors and hedge funds have recently made changes to their positions in HQL. Future Financial Wealth Managment LLC bought a new stake in shares of Abrdn Life Sciences Investors during the first quarter valued at approximately $27,000. Matisse Capital bought a new stake in shares of Abrdn Life Sciences Investors during the fourth quarter valued at approximately $135,000. Blue Bell Private Wealth Management LLC increased its position in shares of Abrdn Life Sciences Investors by 60.4% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 10,125 shares of the company's stock valued at $136,000 after acquiring an additional 3,811 shares in the last quarter. Eudaimonia Partners LLC bought a new stake in shares of Abrdn Life Sciences Investors during the first quarter valued at approximately $142,000. Finally, International Assets Investment Management LLC increased its position in shares of Abrdn Life Sciences Investors by 3,424.5% during the fourth quarter. International Assets Investment Management LLC now owns 11,067 shares of the company's stock valued at $149,000 after acquiring an additional 10,753 shares in the last quarter. Institutional investors own 32.21% of the company's stock.

About Abrdn Life Sciences Investors

Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries.